Chinese Neurosurgical Journal review links fatty acid metabolism to glioma resistance

A review in Chinese Neurosurgical Journal says altered fatty acid metabolism helps glioma grow, evade immunity and resist treatment, making lipid pathways a potential target for future therapies. The paper, published July 31, 2026, also warns that most of the evidence is preclinical and that clinical validation is still needed.

Why it matters: - Glioblastoma remains one of the deadliest adult brain cancers, with median overall survival of about 14 to 16 months. - Standard care still leaves many tumors resistant to surgery, radiation and chemotherapy. - The review argues that fatty acid metabolism could offer a new way to attack tumor growth and treatment resistance at the same time.

What happened: - Researchers led by Dr. Wei Zhang and Dr. Guanzhang Li at Capital Medical University reviewed how altered fatty acid metabolism affects glioma biology and therapy response. - The paper was published in Volume 12 of Chinese Neurosurgical Journal on July 31, 2026. - The review covers fatty acid synthesis, transport, storage, breakdown and elongation in glioma.

The details: - The paper links fatty acid metabolism to tumor growth, invasion, angiogenesis, the tumor microenvironment and treatment resistance. - Fatty acids help build cell membranes and generate signaling molecules that affect proliferation and inflammation. - The review focuses on fatty acid synthase (FASN), fatty acid-binding protein 7 (FABP7) and enzymes involved in protein palmitoylation. - FASN activity is tied to mechanisms that may complicate glioblastoma treatment. - After radiotherapy, glioma cells can accumulate unsaturated fatty acids and lipid droplets that may reduce stress and support survival. - FASN-related signaling has been linked to microglia recruitment and an immunosuppressive tumor environment. - FABP7 can influence fatty acid transport, gene regulation, tumor cell proliferation and glioma stem cell migration. - Stearoyl-CoA desaturase 1 (SCD1) is associated with temozolomide resistance. - Diacylglycerol acyltransferase 1 (DGAT1) may be associated with radioresistance. - Monoacylglycerol lipase (MAGL) may support stem cell self-renewal and immunosuppressive macrophage activity. - The review also discusses preclinical strategies that target epidermal growth factor receptor (EGFR) signaling and fatty acid synthesis. - A phase II trial in recurrent high-grade astrocytoma found the FASN inhibitor TVB-2640 plus bevacizumab was associated with a 6-month progression-free survival rate of 31.4%, compared with a historical 16% for bevacizumab alone. - A phase III trial of an FASN inhibitor plus bevacizumab in recurrent glioblastoma is ongoing, but results have not been published.

Between the lines: - The review positions lipid metabolism as a bridge between tumor biology, immune suppression and therapy failure. - That makes fatty acid pathways attractive targets, but also risky, because lipid metabolism is important in neurons and immune cells. - The blood-brain barrier remains a major obstacle for drug delivery to gliomas. - Most of the proposed targets still rest mainly on preclinical evidence, not routine clinical proof.

What's next: - Future studies need to identify which patients are most likely to benefit from metabolic targeting. - Researchers will need to separate tumor-specific lipid targets from pathways needed by healthy tissue. - Safer drug-delivery methods will be essential before these approaches can move into routine care. - Clinical validation will determine whether combining metabolic interventions with established glioma treatments improves outcomes.

The bottom line: - Fatty acid metabolism is emerging as a promising glioma research target, but it is not yet an established treatment strategy.